Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
26 March 2025
| Name: | BENITEC BIOPHARMA LIMITED (BLT) | |||||||||
| ISIN: | AU000000BLT8 | |||||||||
| Date of Listing: | 17 February 1997 | |||||||||
| Date of Delisting: | 16 April 2020 | |||||||||
| Former Names: |
|
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 16 April 2020.Legal Status:
To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. We have not therefore verified the current legal status of this entity. If you have questions about your shareholding, as we say elsewhere, they may be taken up here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.Capital Gains Tax (CGT) Status:
To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. You will need to seek independent tax advice in relation to Capital Gains Tax or other tax matters but any other enquiries relating to your shareholding in the company should be followed up via our online form here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| BENITEC BIOPHARMA LIMITED | 25/11/2011 | |
| BENITEC LIMITED | 30/04/2002 | 25/11/2011 |
| QUEENSLAND OPALS NL | 30/04/2002 |
REGISTRY:
Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
delisted from the close of trading on Thursday, 16 April 2020 pursuant to Listing rule 17.11. | 16/04/2020 |
we understand the company changed its domicile from Australia to the United States with Benitec Biopharma Inc acquiring all the shares in BLT and issuing one share in Benitec Biopharma Inc for every 300 BLT shares - Benitec Biopharma Inc will trade on Nasdaq under the symbol BNTC | 16/04/2020 |
The previously announced scheme of arrangement to redomicile from Australia to the United States has been fully implemented today. The redomiciliation was approved by Benitec shareholders at a Scheme Meeting held on 26 March 2020, and approved by the Supreme Court of Queensland on 30 March 2020. Benitec Biopharma is now the sole shareholder in the company and is the ultimate parent company of the group. | 15/04/2020 |
Formal notice was given by the company to NASDAQ on April 2, 2020 (Pacific Time) of the intention to voluntarily delist the company's listed warrants from the NASDAQ Capital Market in connection with the completion of the scheme of arrangement to re-domicile the Benitec group from Australia to the United States of America. | 03/04/2020 |
The Foreign Investment Review Board has now confirmed that the new changes to the foreign investment regime do not apply to agreements entered into prior to 10.30pm (AEDT) on 29 March 2020. As the Company and Benitec Biopharma Inc. entered into the Amended and Restated Scheme Implementation Agreement on 30 January 2020, US Holdco will not be required to notify FIRB in respect of the scheme of arrangement. | 31/03/2020 |
The securities of Benitec Biopharma Limited will be suspended from quotation immediately under Listing Rule 17.2, following lodgement of the Supreme Court of Queensland orders with the Australian Securities and Investments Commission approving the scheme of arrangement by which Benitec Biopharma Inc. will acquire all of the issued shares in BLT. | 30/03/2020 |
we understand that on or about this date the company consolidated its shares 1 for 25 | 19/07/2013 |
The suspension of trading in the securities of Benitec Biopharma Limited will be lifted immediately, following receipt of an announcement in relation to the completion of a capital raising. | 06/06/2013 |
The securities of Benitec Biopharma Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of a proposed capital raising. Security Code: BLT | 05/06/2013 |
The suspension of trading in the securities of Benitec Biopharma Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the completion of a capital raising. Security Code: BLT | 05/03/2013 |
Benitec Biopharma Limited (ASX:BLT) advises that the proposed capital raising is not yet finalised and as a result the voluntary suspension will remain in place pending a further announcement on or before Tuesday 5 March 2013 regarding the outcome of the capital raising. | 28/02/2013 |
The securities of Benitec Biopharma Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of a proposed capital raising. Security Code: BLTThe securities of Benitec Biopharma Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of a proposed capital raising. Security Code: BLT | 27/02/2013 |
name changed from Benitec Limited | 25/11/2011 |
delisted from the close of trading on Thursday, 16 April 2020 pursuant to Listing rule 17.11. | 16/04/2020 |
we understand the company changed its domicile from Australia to the United States with Benitec Biopharma Inc acquiring all the shares in BLT and issuing one share in Benitec Biopharma Inc for every 300 BLT shares - Benitec Biopharma Inc will trade on Nasdaq under the symbol BNTC | 16/04/2020 |
The previously announced scheme of arrangement to redomicile from Australia to the United States has been fully implemented today. The redomiciliation was approved by Benitec shareholders at a Scheme Meeting held on 26 March 2020, and approved by the Supreme Court of Queensland on 30 March 2020. Benitec Biopharma is now the sole shareholder in the company and is the ultimate parent company of the group. | 15/04/2020 |
Formal notice was given by the company to NASDAQ on April 2, 2020 (Pacific Time) of the intention to voluntarily delist the company's listed warrants from the NASDAQ Capital Market in connection with the completion of the scheme of arrangement to re-domicile the Benitec group from Australia to the United States of America. | 03/04/2020 |
The Foreign Investment Review Board has now confirmed that the new changes to the foreign investment regime do not apply to agreements entered into prior to 10.30pm (AEDT) on 29 March 2020. As the Company and Benitec Biopharma Inc. entered into the Amended and Restated Scheme Implementation Agreement on 30 January 2020, US Holdco will not be required to notify FIRB in respect of the scheme of arrangement. | 31/03/2020 |
The securities of Benitec Biopharma Limited will be suspended from quotation immediately under Listing Rule 17.2, following lodgement of the Supreme Court of Queensland orders with the Australian Securities and Investments Commission approving the scheme of arrangement by which Benitec Biopharma Inc. will acquire all of the issued shares in BLT. | 30/03/2020 |
we understand that on or about this date the company consolidated its shares 1 for 25 | 19/07/2013 |
The suspension of trading in the securities of Benitec Biopharma Limited will be lifted immediately, following receipt of an announcement in relation to the completion of a capital raising. | 06/06/2013 |
The securities of Benitec Biopharma Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of a proposed capital raising. Security Code: BLT | 05/06/2013 |
The suspension of trading in the securities of Benitec Biopharma Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the completion of a capital raising. Security Code: BLT | 05/03/2013 |
Benitec Biopharma Limited (ASX:BLT) advises that the proposed capital raising is not yet finalised and as a result the voluntary suspension will remain in place pending a further announcement on or before Tuesday 5 March 2013 regarding the outcome of the capital raising. | 28/02/2013 |
The securities of Benitec Biopharma Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of a proposed capital raising. Security Code: BLTThe securities of Benitec Biopharma Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of a proposed capital raising. Security Code: BLT | 27/02/2013 |
name changed from Benitec Limited | 25/11/2011 |
Your browser may reflect a date of printing in American format.
What happened to my shares in Benitec after they delisted.?? | 27/07/2022 17:11:50 |
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 27/03/2020 | Peter Francis | 875,000 | $0.031 | $27,158 | |
| 28/05/2018 | Megan Boston | 100,000 | $0.171 | $17,056 | |
| 30/01/2015 | John Chiplin | On market | 63,020 | $0.720 | $45,500 |
| 05/03/2014 | Peter French | On market | 9,939 | $2.012 | $19,996 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Jerel Banks | Executive Chairman | 26/10/2016 |
| Peter Francis | Non Exec Chairman | 08/02/2006 |
| Cliff Holloway | COO | 24/08/2016 |
| Bryan Dulhunty | CFO | 01/07/2016 |
| Kevin Buchi | Non Exec Director | 11/04/2013 |
| Megan Boston | Executive Director | 16/08/2016 |
| Edward Smith | Director | 15/04/2020 |
| Oliver Kidd | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Greg West | CEO, CFO | 01/08/2011 | 15/06/2018 |
| John Chiplin | Non Exec Director | 01/02/2010 | 23/10/2017 |
| Iain Ross | Non Exec Director | 01/06/2010 | 30/09/2016 |
| Peter French | Managing Director, CEO | 04/06/2010 | 09/12/2015 |
| Melvyn Bridges | Non Exec Director | 12/10/2007 | 19/06/2014 |
| Sue MacLeman | CEO | 04/09/2006 | 29/03/2010 |
| Ken Reed | Non Exec Director | 16/04/2009 | |
| Michael Dalling | Non Exec Director | 24/03/2006 | 26/02/2008 |
| Mike Catelani | CFO | 22/06/2006 | |
| Sara Cunningham | Executive Director | 18/01/2005 | 22/06/2006 |
| Alexander Cappello | Non Exec Director | 03/02/2005 | 17/04/2006 |
| Raymond Whitten | Executive Chairman | 28/11/2002 | 23/02/2006 |
| Robert Thomas | Non-Executive | 07/05/2004 | 30/11/2005 |
| John McKinley | Non Exec Director | 22/04/2002 | 15/11/2005 |
| Gary Taylor | Company Secretary | 23/07/2002 | 01/03/2005 |
| Michael Cox | Executive Director | 01/01/1999 | 19/12/2003 |
| James Anderson | Managing Director | 10/09/2002 | 30/06/2003 |
| Graeme Woodrow | Executive Director | 10/09/2002 | 30/06/2003 |
| John Mattick | Non Exec Director | 04/06/2002 | 04/10/2002 |
| Charles Furness | Finance Director | 22/04/2002 | 23/07/2002 |
| Raymond Iacano | Non Exec Director | 01/06/2000 | 04/06/2002 |
| Rodney Austin | Non Exec Director | 01/01/1996 | 22/04/2002 |
| Peter Gray | Non Exec Director | 01/06/2000 | 22/04/2002 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
